Can Nektar’s 52-week REZOLVE-AA update strengthen the case for rezpegaldesleukin in alopecia areata?
Nektar will discuss 52-week REZOLVE-AA data for rezpegaldesleukin on April 20. Find out what the alopecia areata catalyst could mean.
Pharma & Biotech
Pharma & Biotech
Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?
Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.
Pharma & Biotech
Why CUE-401’s IMMUNOLOGY2026 data could matter for autoimmune drug pipelines
Cue Biopharma, Inc. unveils new CUE-401 data. Find out what this means for autoimmune therapy development and the regulatory path ahead.
Pharma & Biotech
PharmaEssentia expands beyond Taiwan with Puerto Rico plant as BESREMi growth plans widen
PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.
Pharma & Biotech
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech's obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
Pharma & Biotech
Why Hoth Therapeutics’ exon-skipping patent matters more for strategy than near-term value
Hoth Therapeutics secures a U.S. patent for exon-skipping allergy therapy. Read what this means for immunology strategy, clinical risk, and future drug development.
Pharma & Biotech
WuXi Biologics to support Vertex’s autoimmune TCE R&D with full CRDMO integration
Vertex licenses trispecific TCE from WuXi Biologics for autoimmune drug R&D. Explore platform risks, modality fit, and strategic expansion in this analysis.
Pharma & Biotech
Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development
Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.
Pharma & Biotech
J&J ends JNJ-5939 trial early in atopic dermatitis after missing efficacy mark
Johnson & Johnson (J&J) announced that its investigational candidate JNJ-95475939 (JNJ-5939) failed to meet prespecified efficacy criteria in the DUPLEX-AD Phase 2b trial for moderate to severe atopic dermatitis. Following an interim analysis, the study was terminated early. Despite showing a favorable tolerability profile, the molecule did not demonstrate sufficient clinical efficacy to warrant continuation.
Pharma & Biotech
Ustekinumab biosimilar approved in Japan: Can Samsung Bioepis expand its global autoimmune footprint?
Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia's biosimilar adoption. Find out what this means.